Charmaine Tan's Journey with Metastatic Colon Cancer: A Case Study of Hope and Healing

Understanding Metastatic Colon Cancer

Charmaine Tan, a 60-year-old woman from Malaysia, faced a daunting battle with metastatic colon cancer. When she was first referred to the ECCT medical team, her condition was alarming and complex. She had been living with this aggressive cancer for over two years. By the time she sought help, the disease had spread significantly. Imaging revealed that nearly 80% of her liver was affected by metastatic lesions, with multiple nodules present in both lungs. Charmaine was visibly jaundiced, struggled with respiratory discomfort, and was physically weakened after undergoing extensive treatments, including surgery, chemotherapy, and radiotherapy. Despite these efforts, her condition continued to deteriorate.

Initial Assessment and Challenges

At the outset, Charmaine's laboratory findings reflected the severity of her metastatic colon cancer. Her tumor markers were alarmingly high, with a CEA level of 1955.4 and CA 19-9 of 773. These elevated values indicated a significant tumor burden and active metastatic progression. Additionally, her bilirubin levels were notably raised, signaling severe liver impairment. Clinically, she exhibited fatigue, poor appetite, and general weakness. Her capacity for further conventional systemic therapy had become limited. At this stage, her oncology management focused primarily on stabilization and supportive care rather than aggressive treatment escalation.

On October 14, 2025, under careful clinical supervision and in conjunction with her ongoing oncology care, Charmaine began integrating ECCT into her treatment plan for metastatic colon cancer. The goal was not to replace conventional therapy but to provide additional biological support at a time when options were dwindling and her systemic resilience was compromised.

Positive Changes Over Time

In the weeks that followed, follow-up assessments began to show significant changes. Comparison of CT scans between September 17, 2025, and January 8, 2026, demonstrated real improvement, not merely stability.

Liver Findings

• The largest liver lesion reduced from 9.8 cm to 7.6 cm.

• Slight reductions in the sizes of multiple other hepatic metastases.

• No new liver lesions were identified.

• No worsening portal vein compression was observed.

  
  

This represents objective measurable reduction in tumor size within the liver.

Before and After ECCT - Liver CT Scan

Lung Findings

• Previously described as “increased in size and number.”

• On the January 2026 scan: stable in size and number.

• Some nodules demonstrated central cavitation, which may reflect internal tumor necrosis.

• No new pulmonary nodules were reported.

  
  

This represents stabilization rather than further progression.

Radiologic Conclusion

Compared to September 2025, the January 2026 scan demonstrates:

• Measurable reduction in the dominant liver mass.

• Overall slight reduction in hepatic metastases.

• Stabilization of lung metastases.

• No new metastatic spread.

  
  

This qualifies as partial regression with disease stabilization. While it is not a complete response, it clearly indicates that the disease is not progressing. The overall radiologic assessment reflects improvement.

Tumor Marker Improvements

Most significantly, Charmaine's tumor markers showed a dramatic decline after introducing ECCT. CEA decreased from 1955.4 to 56.3, and CA 19-9 fell from 773 to 33, representing more than a 95 percent reduction in both markers. Such a consistent downward trend suggests a meaningful reduction in tumor biological activity. In advanced metastatic disease, tumor markers often provide early insight into biological response, even when residual masses remain visible on imaging.

Clinical Improvements

Beyond laboratory and radiologic findings, Charmaine’s overall clinical condition improved in parallel. Her hemoglobin rose from 10 g/dL to 15 g/dL, indicating recovery in systemic strength. Her sleep improved, bowel function stabilized, and she remained mentally alert, communicative, and ambulatory. Although her appetite remained variable, there were clear signs of regained resilience compared to her initial presentation.

Continuing the Journey

Today, Charmaine continues her cancer care journey with ongoing monitoring and tailored therapy. Her case illustrates that in advanced metastatic disease, meaningful progress is not always defined by dramatic radiologic shrinkage alone. Stabilization of disease, reduction in tumor markers, and improvement in systemic function can represent an important shift in overall trajectory, particularly in a situation that had previously been trending toward rapid deterioration.

Conclusion: A Path Forward

Charmaine's journey highlights the importance of exploring alternative and complementary treatments like ECCT. For patients facing similar challenges, understanding the potential benefits of such therapies can provide hope and a renewed sense of agency in their treatment journey. As the field of cancer care evolves, integrating innovative approaches may lead to improved outcomes and quality of life for many individuals navigating the complexities of cancer treatment.

In conclusion, Charmaine Tan's story serves as a testament to resilience and the potential for recovery, even in the face of daunting odds. Her experience underscores the importance of comprehensive care that addresses both the physical and emotional aspects of living with cancer.